Our gastroenterology and hepatology teams understand the broad spectrum of digestive disorders
Every year, an estimated 60-70 million people are affected by gastrointestinal diseases in the U.S. alone.1 Across the world, novel therapies are desperately needed in both gastroenterology and hepatology. We have a dedicated 800-strong gastroenterology/hepatology team who understand the broad spectrum of digestive disorders.
We have experience across adult and pediatric gastroenterology and hepatology clinical trials
Specializing in Phase I to IV studies, we help to bring a diverse range of therapies to an equally diverse range of markets, delivering projects ranging from strategic clinical development planning to single- or multi-phase clinical programs.
We work closely with gastroenterologists, hepatologists, primary care investigators and Key Opinion Leaders across the globe to ensure that the strategies we develop for you are built on the best network and knowledge in the business.
Our adult and pediatric clinical study experience includes anal fissures, celiac disease, colitis, colorectal disorders, constipation disorders, diverticulitis, gastroenteritis, gastroesophageal reflux disease (GERD), gastric surgery (including band devices), gastric ulcers, hepatic cirrhosis/fibrosis, inflammatory bowel disease (IBD) including Crohn’s Disease and ulcerative colitis, irritable bowel syndrome (IBS), non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), nausea and vomiting, pancreatitis, and short bowel syndrome.
1 Everhart JE, Ruhl CE. Burden of digestive diseases in the United States part I: overall and upper gastrointestinal diseases. Gastroenterology. 2009; 136:376–386. [PubMed: 19124023]